Givinostat Continues to Delay DMD Progression in Long-term Study, New Data Show

Givinostat Continues to Delay DMD Progression in Long-term Study, New Data Show

287453

Givinostat Continues to Delay DMD Progression in Long-term Study, New Data Show

Treatment with givinostat alongside corticosteroids continues to delay disease progression — and maintain patients’ ability to walk — in boys with Duchenne muscular dystrophy (DMD), new data from a long-term Phase 2/3 clinical study show. The new data, from an ongoing seven-year study, was presented by Paolo Bettica, MD, PhD, chief medical officer at Italfarmaco, givinostat’s maker, at the virtual 28th International Conference on Duchenne and Becker Muscular Dystrophy, held online Feb. 20. “We are…

You must be logged in to read/download the full post.